Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233115 | 0.93 | FTO (0.40) | FTOKDM1AHSD17B1CYP19A1ESR1 | |
| Ammonia Solution, Strong SCHEMBL28596997 | 0.88 | RXRA (0.40) | FTOHSD17B1CYP19A1ESR1HPGD | |
| SCHEMBL8678472 | 0.84 | ALDH1A1 (0.46) | ESR1ESR2HPGDHSD17B10RXRA | |
| SCHEMBL22477463 | 0.84 | ALDH1A1 (0.46) | ESR1ESR2HPGDHSD17B10RXRA | |
| SCHEMBL10323390 | 0.79 | RXRA (0.40) | CYP19A1ESR1ESR2HPGDHSD17B10 | |
| SCHEMBL1496260 | 0.78 | CYP19A1 (0.39) | HSD17B1CYP19A1ESR1ESR2HPGD | |
| SCHEMBL1496245 | 0.78 | CYP19A1 (0.38) | CYP19A1ESR1ESR2HPGDHSD17B10 | |
| SCHEMBL22589962 | 0.77 | ESR1 (0.35) | KDM1AESR1ESR2RXRAALDH1A1 | |
| SCHEMBL4226427 | 0.76 | RXRA (0.40) | CYP19A1ESR1ESR2HPGDHSD17B10 | |
| SCHEMBL25027587 | 0.75 | KARS1 (0.43) | ESR1ESR2HPGDHSD17B10RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051331-B2 | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2015-06-09 | — | — | US | disclosed |
| CN-102498116-B | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | SANOFI AVENTIS | 2014-08-06 | — | — | CN | disclosed |
| EP-2477994-B1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2013-12-11 | — | — | EP | disclosed |
| EP-2477994-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20120184566-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| WO-2011034830-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184566-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | FTO 2368/4885KDM1A 1151/4885HSD17B1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.